For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
VivoTag 800 fluorochrome is an amine-reactive near-infrared fluorochrome for coupling via a NHS ester linkage to peptides, small molecules, proteins, antibodies or macromolecules. Available is 5 mg quantity.
|Fluorescent Agent Type||Labeling|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||VivoTag|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Unit Size||5 mg|
|Wave Length||800 nm|
VivoTag® 800 is a red fluorescent labeling agent containing an N-hydroxysuccinimide (NHS)-ester. Labeling reagents, such as VivoTag 800 reagent, are commonly used for labeling proteins. The NHS ester moiety reacts with amino groups at pH 7-9 to form stable amide bonds. Lysines within proteins, including antibodies, are available as targets for this chemical conjugation.,Protein labeling efficiency may vary depending upon the type of protein labeled, so different conjugation ratios may need to be attempted to attain success. For Near Infrared fluorophore conjugation, ratios of fluorophore to protein of 4:1 have been seen to generate effective imaging agents. Not all antibodies or proteins (independent of target specificity) make good imaging agents, due to long half-lives and/or excessive accumulation in non-target sites.
VivoTag® 800 is an amine reactive (NHS Ester) near-infrared (NIR) fluorochrome for labeling biomolecules for in vivo imaging applications.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.